Alterations in urinary microbiota composition in urolithiasis patients: insights from 16S rRNA gene sequencing

Front Cell Infect Microbiol. 2023 Oct 31:13:1266446. doi: 10.3389/fcimb.2023.1266446. eCollection 2023.

Abstract

Objectives: To investigate the urinary microbiota composition in urolithiasis patients compared to healthy controls and to identify potential microbial markers and their association with clinical parameters.

Methods: A total of 66 samples, comprising 45 from urolithiasis patients and 21 from healthy controls, were analyzed. 16S rRNA gene sequencing was employed to determine the microbiota composition. Various statistical and bioinformatics tools, including ANOVA, PCoA, and LEfSe, were utilized to analyze the sequencing data and identify significant differences in microbial abundance.

Results: No significant demographic differences were observed between the two groups. Post-quality control, clean tags ranged from 60,979 to 68,736. Significant differences in α-diversity were observed between the two groups. β-diversity analysis revealed distinct clustering of the urinary microbiota in urolithiasis patients and controls. Notably, Ruminococcaceae was predominant in urolithiasis samples, while Proteobacteria was more prevalent in healthy samples. Lactobacillus was significantly overrepresented in samples from healthy females.

Conclusion: The urinary microbiota composition in urolithiasis patients is distinct from that of healthy controls. Specific microbial taxa, such as Ruminococcaceae and Proteobacteria, could serve as potential biomarkers for urolithiasis. The findings pave the way for further exploration of the role of microbiota in urolithiasis and the development of microbiome-based therapeutic strategies.

Keywords: 16S rRNA gene sequencing; clinical correlations; microbial diversity; urinary microbiota; urolithiasis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Female
  • Gastrointestinal Microbiome* / genetics
  • Genes, rRNA
  • Humans
  • Microbiota* / genetics
  • Proteobacteria / genetics
  • RNA, Ribosomal, 16S / genetics
  • Urolithiasis* / genetics

Substances

  • RNA, Ribosomal, 16S

Grants and funding

This work was supported by the National Natural Science Foundation of China (81802827, 81630019, 82100808). Scientific Research Foundation of the Institute for Translational Medicine of Anhui Province (2017ZHYX02). China Postdoctoral Science Foundation (2021M690185), the Anhui Postdoctoral Science Foundation (2021A482) and the Anhui Provincial Department of Education Research Project (KJ2020A0167).